canakinumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4952	914613-48-2

Description:

Molecule	Description
Synonyms: canakinumab ilaris ACZ885	a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

canakinumab
ilaris
ACZ885

a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.70	mg	P

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
June 17, 2009	FDA	NOVARTIS PHARMS
Oct. 23, 2009	EMA
Sept. 26, 2011	PMDA	Novartis Pharma K.K.

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	797.82	18.24	349	8107	103616	63376950
Haemophagocytic lymphohistiocytosis	306.55	18.24	95	8361	10532	63470034
Pyrexia	297.14	18.24	337	8119	470141	63010425
Incorrect dose administered	171.46	18.24	104	8352	59864	63420702
Serum ferritin increased	116.24	18.24	40	8416	6142	63474424
Serum amyloid A protein increased	114.42	18.24	22	8434	314	63480252
COVID-19	88.08	18.24	91	8365	113012	63367554
Illness	79.74	18.24	60	8396	48999	63431567
Clubbing	79.24	18.24	17	8439	429	63480137
Condition aggravated	70.43	18.24	161	8295	402056	63078510

Showing 1 to 10 of 58 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Apparent death	1011.78	27.66	227	9215	3417	34944072
Diverticulitis	701.81	27.66	246	9196	19758	34927731
Joint swelling	481.41	27.66	260	9182	59630	34887859
Deep vein thrombosis	396.50	27.66	236	9206	65012	34882477
Inappropriate schedule of product administration	390.74	27.66	230	9212	62066	34885423
Pulmonary thrombosis	386.38	27.66	123	9319	7284	34940205
Red blood cell sedimentation rate increased	372.49	27.66	126	9316	9036	34938453
Pulmonary embolism	360.33	27.66	250	9192	89496	34857993
Terminal state	302.13	27.66	88	9354	3846	34943643
Renal failure	269.49	27.66	246	9196	130311	34817178

Showing 1 to 10 of 46 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	594.72	20.03	337	13372	133291	79597388
Apparent death	421.57	20.03	98	13611	2767	79727912
Pulmonary thrombosis	308.63	20.03	105	13604	12066	79718613
Haemophagocytic lymphohistiocytosis	306.97	20.03	122	13587	21715	79708964
Terminal state	280.98	20.03	79	13630	4810	79725869
Pyrexia	276.85	20.03	449	13260	678260	79052419
Red blood cell sedimentation rate increased	223.09	20.03	123	13586	45819	79684860
Diverticulitis	212.15	20.03	119	13590	45817	79684862
Incorrect dose administered	188.21	20.03	133	13576	76497	79654182
C-reactive protein increased	179.03	20.03	160	13549	128867	79601812

Showing 1 to 10 of 73 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L04AC08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors

Showing 1 to 1 of 1 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Familial Mediterranean fever	indication	12579009	DOID:2987
Articular gout	indication	48440001	DOID:13189
Deficiency of mevalonate kinase	indication	124327008	DOID:0050452
Systemic onset juvenile chronic arthritis	indication	201796004
TNF receptor-associated periodic fever syndrome (TRAPS)	indication	403833009
Cryopyrin associated periodic syndrome	indication	430079001

Showing 1 to 6 of 6 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-1 beta	Cytokine	P01584	IL1B_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
013212	NDDF
165731	MMSL
26503	MMSL
37CQ2C7X93	UNII
4028805	VUID
4028805	VANDF
6773	IUPHAR_LIGAND_ID
698091001	SNOMEDCT_US
703376008	SNOMEDCT_US
853491	RXNORM

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ilaris	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0734	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Ilaris	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0734	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Ilaris	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0734	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections

Showing 1 to 3 of 3 entries

Previous1Next